Where is the shortcoming of domestic medical device innovation reform?
In recent years, the level of innovation in domestic medical devices has improved, but the original innovation capability is still insufficient. China's medical device market is still dominated by imported products. What is the "upper position" that restricts domestic medical devices? In the recent domestic medical device innovation development salon co-sponsored by the Chinese Medical Association Cardiovascular Branch and the People's Political Consultative Conference Newspaper, clinicians, government officials, and enterprise representatives have "put a pulse" for domestic medical devices.
Clinical and production disjointed
The doctor can't be a visitor
Huo Yong, member of the National Committee of the Chinese People's Political Consultative Conference and chairman of the Cardiovascular Branch of the Chinese Medical Association, said that in 2013, the number of cardiac interventions in China exceeded 450,000, and nearly 700,000 stents were used, of which domestic stents accounted for 3/4 of the market. “But the original things are not in our hands, although we may have some partial or detailed improvements, such as the earliest we produced a biodegradable drug-coated stent in the world, but there is no original original product. Huo Yong said.
Huo Yong pointed out that medical device innovation, companies may have good ideas, but their clinical needs and shortcomings of the device may not be as clear as doctors. To improve the level of innovation in domestic medical devices requires everyone to paddle, especially for doctors. Now Chinese doctors lack this awareness, and more importantly, lack of motivation. How to protect intellectual property rights and how to distribute benefits is not clear.
Huo Yong said that policies and research funds should be introduced to encourage clinicians to participate in medical device research and development. "At present, the People's Hospital of Jiangsu Province has carried out a useful exploration. The hospital stipulates that doctors' innovations are owned by themselves, and 80% of the benefits are attributed to the doctors themselves."
Policy-oriented problems
Looking forward to aggressive pricing policy
"China's medical device market is still dominated by imported products. Even domestically produced medical devices of superior quality and reasonable price are still relatively low. The dental implants of Peking University Stomatological Hospital are mainly imported. Yu Guangyan, a member of the National Committee of the Chinese People's Political Consultative Conference and former dean of the Peking University Stomatological Hospital, said that there are business reasons, such as poor after-sales service by some manufacturers or sales departments, and low user satisfaction. There are also personal reasons, such as patients and their families requesting the use of imported medical care. Instruments, medical staff are not actively using domestic products.
"There is a certain problem in the national policy orientation. For example, under the premise of equal quality, the bidding price of domestic medical equipment is low." Dong Heyan, member of the Liaoning Provincial Political Consultative Conference and chairman of Liaoning Biomedical Materials Research and Development Center Co., Ltd., said that the current domestic heart There is almost no difference in the technical level between the stent and the imported heart stent, but in the bidding pricing, the average unit price of the domestic stent is 0.8 million yuan, and the average unit price of the imported stent is 16,000 yuan, which is 1 time difference. In the case of orthopedic implant devices, the gap is even more It is up to 2 times to 3 times. In addition, domestically produced innovative products have not received support policies on pricing, which is not conducive to the healthy development of China's medical device industry in the long run.
Dong Heyan said that at present, China's high-tech enterprises pay VAT and income tax at the rate of 17% and 25% respectively, and the tax burden is heavier. It is recommended that the state levy taxes on domestically-supported enterprises at a rate of 4% compared with bio-product companies, and reduce corporate tax burden.
Yu Guangyan suggested that China should learn from the experience of Japan and South Korea and introduce strong policies to promote the development of the medical device industry in the country, such as setting up research funds for domestic medical device research and development, vigorously supporting product research and development of related companies, and strengthening scientific research cooperation between enterprises and medical researchers. .
Face Mask,3 Layer Dust Mask,Face Mask Medical,Eco-Friendly Face Mask
KUTA TECHNOLOGY INDUSTRY CO.,LIMITED , https://www.kutasureblue.com